Medicare price talks defended by DoJ
Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
She learned that she would have to try, and "fail," on two other drugs before Medicare would cover the new one.
In February 2025, a rumor spread that Medicare would stop covering telehealth services — which allow patients to access ...
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
The U.S. agency that oversees Medicare is taking out questions on enrollment application forms that ask people about their ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
President Donald Trump likely won't do away with a process that allows Medicare to negotiate drug prices with manufacturers, even as he erases Joe Biden's other policy accomplishments. But Trump ...
On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback